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Summary Preoperative serum levels of CEA and CA 242 were determined in 260 patients with colorectal
cancer and in 92 patients with benign colorectal diseases. The overall sensitivity of the CEA test was 43% and
of the CA 242 test 39%. The corresponding specificities were 90% and 87% respectively, using 5 ngml-' as
cut-off level for CEA and 20 U ml-' for CA 242. The sensitivity of CEA was 26%, 32%, 38% and 77% for
Dukes A, B, C and D colorectal cancer, and the sensitivity of CA 242 was 26%, 26%, 40% and 67%,
respectively. The correlation between CEA and CA 242 was low. Concomitant elevation of both markers was
seen in 5%, 12%, 18% and 59% of patients with Dukes A, B, C and D colorectal cancer, respectively. Of all
the patients, 23% showed elevation of both the CEA and the CA 242 level, whereas CEA alone was elevated
in 20% and CA 242 alone in 15% ofthe patients with colorectal cancer. Combined use of both markers raised
the overall sensitivity from 43% to 58%, but reduced the specificity from 90% to 80%. The increase in
sensitivity by combining the two markers was most marked in Dukes A, B and C colorectal cancer. Either or
both of the markers were elevated in 46%, 46% and 60% of the patients respectively. The clinical value of
combining CEA and CA 242 seems very promising and should be further investigated in prospective
studies.
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CEA, detected almost 30 years ago (Gold and Freedman,
1965), is the only clinically established marker for pre-
operative diagnosis and follow-up of patients with colorectal
cancer (Brummendorf et al., 1985; Roberts, 1988; Minton
and Chevinsky, 1989; Kuusela et al., 1991). Because of a low
sensitivity in early stages of colorectal cancer, CEA is not an
ideal marker for preoperative diagnosis (Brummendorf et al.,
1985; Roberts, 1988; Kuusela et al., 1991; Nilsson et
al.,1992). However, CEA shows high sensitivity for recurrent
colorectal cancer. Some investigators advocate second-look
operation of patients lacking clinical signs or symptoms of
recurrence if the CEA level rises during follow-up (Minton
and Chevinsky, 1989). During recent years, new tumour
markers for the diagnosis of digestive tract cancer have been
introduced, such as CA 19-9, CA 50 and CA 242 (Del
Villano et al., 1983; Holmgren et al., 1984; Nilsson et al.,
1992). High CA 19-9 and CA 50 levels are found particularly
in patients with pancreatic and biliary cancer. Also, in col-
orectal cancer, elevated CA 19-9 and CA 50 levels may be
found, but the sensitivity of these markers is too low for
primary diagnosis of colorectal cancer (Roberts, 1988;
Roberts et al., 1992; Haglund et al., 1992; Nilsson et al.,
1992). The use of CA 19-9 or CA 50 in combination with
CEA has not shown clinical benefit over CEA alone
(Kuusela et al., 1991; Roberts et al., 1992; Nilsson et al.,
1992).
Tumour marker CA 242 is defined by the monoclonal
antibody C 242, which was obtained by immunising mice
with a human colorectal carcinoma cell line, COLO 205
(Lindholm et al., 1985). The structure of the antigenic deter-
minant is not completely defined, but it seems to be a
sialylated carbohydrate structure related to type I chain
(Nilsson et al., 1992). It is related, although not identical, to
the antigenic epitopes of CA 19-9 and CA 50 (Johansson et
al., 1991a, b; Nilsson et al., 1992).
In the serum, the CA 242 epitope has shown to be coex-
pressed with CA 50 and with sialylated Lewisa, i.e. CA 19-9,
on the same macromolecular complex (Johansson et al.,
1991a, b). This has made it possible to set up a solid-phase
immunoassay, in which antibodies against sialylated Lewisa
and the CA 242 antibody are used as 'catcher' and 'detector'
antibodies respectively (Nilsson et al., 1988).
Elevated levels of CA 242 have been found in many
patients with gastrointestinal and pancreatic cancer (Kuusela
et al., 1991; Nilsson et al., 1992; Rothlin et al., 1993; Hag-
lund et al., 1994). The reported preoperative sensitivities and
specificities of CA 242 for colorectal cancer have been pro-
mising, and the figures clearly higher than those of CA 19-9
and CA 50 (Kuusela et al., 1991; Roberts et al., 1992;
Nilsson et al., 1992). According to studies published so far,
the concomitant use of CEA and CA 242 increases the
sensitivity for early colorectal cancer (Kuusela et al., 1991;
Nilsson et al., 1992).
The aim of this study was to investigate the expression of
the CEA and CA 242 levels in the preoperative sera from
patients with colorectal cancer, and to evaluate the advantage
of using both these markers.
Patients
Preoperative serum samples were obtained from 260 patients
with clinically diagnosed and histologically verified colorectal
cancer. Tumours were classified according to the modified
Dukes classification (Tumball et al., 1967). Thirty-nine
patients had Dukes A, 100 patients had Dukes B, 60 patients
had Dukes C and 61 patients had Dukes D colorectal
cancer.
The control group consisted of 92 patients with benign
colorectal diseases. Twenty-four patients had ulcerative col-
itis, 27 patients had colorectal adenomas, 26 patients had
diverticulitis and 15 patients had Crohn's disease. None of
the patients in the control group developed cancer during
follow-up.
Assays
Serum samples were taken preoperatively and stored at -20'C.
The serum levels ofCA 242 were measured by a dissociation-
enhanced lanthanide fluoroimmunoassay (DELFIA) (Wallac
Oy, Turku, Finland), in which antibodies against sialylated
Lewisa are used as solid phase catching antibody and C 242
as detecting antibody as described in previous reports
(Kuusela et al., 1991; Nilsson et al., 1988, 1992). The serum
levels of CEA were quantitated by a commercially available
solid-phase radioimmunoassay (Abbott-Diagnostics, Chicago,
IL, USA).
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Statistical analysis
For the comparison of the tumour markers, cut-off values
representing the 90% and 95% specificity levels of patients
with relevant benign diseases were determined. The sensitivity
and specificity of CEA and CA 242 were also compared by
receiver operating characteristic (ROC) curve analysis (Metz,
1978).
The correlation between CA 242 and CEA was calculated
by linear regression using the logarithms of the serum
levels.
Results
CEA
Using Sngml' as the cut-off level for CEA, the overall
sensitivity was 43% and the specificity 90%. The predictive
value of a positive serum test was 93% and for a negative
(<5ng mli) value 36% (Table I). The preoperative CEA
level was elevated in 26% of the patients with Dukes A, in
32% of the patients with Dukes B, in 38% of the patients
with Dukes C and in 77% of the patients with Dukes D
colorectal cancer (Table II). When the cut-off value of
8ngml1', representing the 95% specificity level of benign
colorectal diseases, was used, the sensitivity of CEA was 8%,
19%, 30% and 69% in Dukes A, B, C and D colorectal
cancer respectively. The overall sensitivity was 32% at this
specificity level (Table III).
The highest CEA level found in Dukes A colorectal cancer
was 11 ngml-', in Dukes B 1453 ngml', in Dukes C 297
Table I Assay parameters for CEA and CA 242 in 260 patients
with colorectal cancer and in 92 patients with benign colorectal
diseases
CA 242 (%) CEA (%)
Sensitivity 39 43
Specificity 87 90
Positive predictive value 89 93
Negative predictive value 33 36
The cut-off level for CEA is 5 ngml' and for CA 242 20 Uml'.
(Sensitivity = true positive/true positive + false negative;
specificity = true negative/true negative + false positive; positive
predictive value = true positive/true positive + false positive; negative
predictive value = true negative/true negative + false negative.)
Table II The sensitivity of CEA and CA 242 in patients with
colorectal cancer, according to stage
Dukes A Dukes B Dukes C Dukes D All
Sensitivity (%) (%) (%) (%) (%)
CEA 26 32 38 77 43
CA 242 26 26 40 67 39
The cut-off level is 5 ngml' for CEA and 20 Uml- for CA 242.
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ngml' and in Dukes D 9000 ngml-', compared with the
highest value of 14 ngmlh' in the control group. The median
values were all below 3 ngml1 ' except in Dukes D colorectal
cancer, where it was 54 ngml1 (Figure 1). In the control
group, serum CEA levels above 5 ngml' were found in
three patients with colorectal adenomas, in two patients with
diverticulitis, in two patients with ulcerative colitis and in one
patient with Crohn's disease.
CA 242
Using 20 UmlP' as the cut-off level for CA 242, the overall
sensitivity was 39% and specificity 87%. The predictive value
of a positive serum test was 89% and for a negative value
(<20Uml-') 33% (Table I).
CA 242 was elevated in 26% of the patients with Dukes A,
in 26% of the patients with Dukes B, in 40% of the patients
with Dukes C and in 67% of the patients with Dukes D
colorectal cancer (Table II).
When the cut-off value of 21 Uml1', representing the 90%
specificity level of benign colorectal diseases, was used, the
sensitivity of CA 242 was 26%, 26%, 38% and 67% for
Dukes A, B, C and D colorectal cancer respectively. At the
95% specificity level (>24 U ml-') the sensitivity of CA 242
was 23%, 23%, 33% and 66% in Dukes A, B, C and D
colorectal cancer respectively. The overall sensitivity was
38% at the 90% specificity level and 35% at the 95%
specificity level (Table III).
The highest CA 242 level in patients with Dukes A colo-
rectal cancer was 144Uml-1, in Dukes B 1000UmlmP, in
Dukes C 265 Uml-', in Dukes D 20000 Uml-' and in the
control group 41 U ml-'. The median values were 8 U ml1',
9 Uml[I 7.5 Uml'I and 105 Uml-' in Dukes A, B, C and
D colorectal cancer respectively and 5 U ml-I in the control
group (Figure 2). In the control group, CA 242 serum levels
above 20Uml-' were found in five patients with colorectal
adenomas, in four patients with ulcerative colitis and in three
patients with diverticulitis.
Comparison and combination ofCEA and CA 242
There was no correlation between the serum levels of CEA
and CA 242 (r2: overall, 0.355; Dukes A, 0.016; Dukes B,
0.092; Dukes C, 0.002; Dukes D, 0.334). When the recom-
mended cut-off levels were used, 20% of the patients (51/260)
had an elevated CEA level and a normal CA 242 level, while
15% (40/260) had an elevated CA 242 level and a normal
CEA level. Both markers were elevated in 61 patients (23%),
of whom 36 patients (59%) had advanced disease (Dukes D
cancer) (Table IV). Either or both of the markers were
elevated in 58% of the patients (152/260).
ROC analysis showed that CEA and CA 242 had similar
sensitivities for colorectal cancer at specificity levels higher
than 90% (false-positive fraction <0.1) (Figure 3). Using the
cut-off values representing the 95% specificity level of benign
colorectal diseases, CEA (>8 ngml-') was positive in 32%
and CA 242 (>24Uml-') in 35% (Figure 1, Table IV).
When requiring either CEA to be higher than 8 ngml-1 or
CA 242 to be higher than 24 U ml', the sensitivity was 50%
and the specificity was 89%.
Table III Sensitivity of CEA and CA 242 for colorectal cancer at the 90% and 95% specificity
levels of patients with benign colorectal diseases
90% specificity level 95% specificity level
CEA CA 242 CEA CA 242
>5 ngml-' >21 Uml-' >8 ngml-' >24 Uml-'
No. % % % %
Dukes A 39 26 26 8 23
Dukes B 100 32 26 19 23
Dukes C 60 38 38 30 33
Dukes D 61 77 67 69 66
Overall 260 43 38 32 35Provwal` CUarWCA 242 In coicrctal cancer PA M~~~~~~~~~~~C
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Table IV Proportion of elevated serum levels of CEA and CA 242 in different combinations in
patients with colorectal cancer, using 5 ngml-' as cut-off level for CEA and 20 U ml as cut-off
level for CA 242
Dukes A Dukes B Dukes C Dukes D All
(% (% (% (% (%
CEA+ CA 242- 21 20 20 18 20
CEA- CA 242k 21 14 22 8 15
CEA
+ CA 242k+ 5 12 18 59 23
CEA+ and/or CA 242k 47 46 60 85 58
CEA- CA 242- 53 54 40 15 42
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Figure 1 Preoperative serum CEA levels of?atients with colorectal cancer and patients with benign colorectal diseases. The dotted
line represents the cut-off level of 5 ngmlP . The median values are shown by a line in each column.
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Figure 2 Preoperative serum CA 242 levels of patients with colorectal cancer and patients with benign colorectal diseases. The
dotted line represents the cut-off level of 20 U mfl The median values are shown by a line in each column.
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Figure 3 Receiver operating characteristic (ROC)
of CEA and CA 242 in colorectal diseases. A
patients with colorectal cancer were used for (
true-positive fraction and 92 patients with bet
diseases were used for calculating the false-positivi
true-positive fraction (TP) reflects the sensitivity c
sitivity = TP x 100%), and the false-positive fra
specificity [specificity = (1-FP) x 100%]. The dot
the 95% specificity level (FP = 0.05).
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In Dukes A colorectal cancer 21% (eight patients) had an
elevated CEA level only, 21% (eight patients) an elevated CA
242 level only, while 5% (two patients) had a concomitant
rise in CEA and CA 242. Both markers were normal in 53%
(21 patients) (Table IV, Figure 4).
In Dukes B cancer, 20% (20 patients) had an abnormal
CEA alone, 14% (14 patients) an abnormal CA 242 alone,
while 12% (12 patients) had both an elevated CEA and CA
242 level. A normal CEA and CA 242 serum level was seen
in 54% (54 patients) of the patients (Table IV, Figure 4).
In Dukes C cancer 20% (12 patients) had an abnormal
CEA alone, 22% (13 patients) an abnormal CA 242 alone
and 18% (11 patients) had a concomitant rise of CEA and
CA 242. Both markers were normal in 40% of the patients
1'r-1-1- TU A AN (able IV, rigure 4).
In Dukes D cancer 18% (11 patients) had an elevated
curve analysis CEA alone, 8% (five patients) an elevated CA 242 alone, and
total of 260 59% (36 patients) both an elevated CEA and CA 242 level.
calculating the A normal CEA and CA 242 serum level was seen in 15%
nign colorectal (nine patients) of the patients (Table IV, Figure 4).
,e fraction. The When combining CEA and CA 242, requiring either or
f the test (sen- both to be elevated, the sensitivities were 47%, 46%, 60%
Lction (FP) the and 85% in patients with Dukes A, B, C and D colorectal
tted line shows cancer respectively (Table IV) (Figure 4). The combination
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Figure 4 Correlation between serum CEA and CA 242 in patients with Dukes A-D colorectal cancer. Dotted lines at 5ngmlh'
for CEA and at 20 U ml-' for CA 242 divide the graph into four areas: patients with an elevated CEA serum level only, patients
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resulted in a significantly higher overall sensitivity of 58%
(P<0.001) compared with either marker alone. The specifi-
city decreased to 80%.
Discussion
CEA is the most widely used tumour marker for colorectal
cancer, although its value in primary diagnosis of colorectal
cancer is questionable (Roberts, 1988; Kuusela et al., 1991;
Roberts et al., 1992; Nilsson et al., 1992). A sensitive and
specific tumour marker for early diagnosis of colorectal
cancer would be of great clinical importance, but none of the
markers available today is sensitive and specific enough. The
sensitivity of CA 19-9 and CA 50 has been shown to be
clearly lower in all stages of colorectal cancer than that of
CEA (Roberts, 1988; Kuusela et al., 1991; Nilsson et al.,
1992). Concomitant use of CEA and CA 19-9 or CA 50,
requiring either or both markers to be elevated, does not
raise the sensitivity markedly compared with CEA. alone
(Kuusela et al., 1987; Roberts, 1988).
Preliminary results on the new tumour marker CA 242
have been promising in patients with colorectal cancer
(Kuusela et al., 1991; Nilsson et al., 1992). Although CA 242
is closely related to CA 19-9 and CA 50, CA 242 has shown
clearly higher sensitivity for colorectal cancer than CA 19-9
and CA 50 (Kuusela et al., 1991; Roberts et al., 1992;
Nilsson et al., 1992). Therefore, a study comparing the
preoperative serum levels of CA 242 with those of CEA was
designed. The sensitivities of both markers proved to be of
the same magnitude in all stage groups. However, there was
no correlation between the serum values of CEA and CA
242, and mostly CEA and CA 242 were elevated in different
patients. Only in Dukes D cancer was there a considerable
overlap between the markers, but still without any correla-
tion. These results are in concordance with our previously
reported preliminary results and with those of Nilsson et al.
(Kuusela et al., 1991; Roberts et al., 1992; Nilsson et al.,
1992). The low correlation between the markers indicates
that CEA and CA 242 are expressed independently, which
further supports the use of these markers concomitantly.
In calculating the specificities and predictive values, we
used a control group consisting of patients with benign colo-
rectal diseases, i.e. diseases relevant for differential diagnosis
of colorectal cancer. Note that the proportion of elevated
CEA and CA 242 values was of the same magnitude as that
of healthy blood donors.
At the 90% specificity level the overall sensitivity was
higher for CEA than for CA 242. However, when raising the
specificity level to 95%, the sensitivity of CEA was clearly
reduced, whereas the sensitivity of CA 242 remained un-
changed and was superior to that of CEA. Combining two
markers always results in reduced specificity. Combining
CEA and CA 242 causes a 7-10% loss in specificity to 80%.
This must be regarded as acceptable when compared with the
15-19% increase in sensitivity to 58%.
In conclusion, this study supports the concomitant use of
CEA and CA 242 in the diagnosis of patients with colorectal
cancer. A combination of CEA and CA 242 increased the
sensitivity in all stages of colorectal cancer, particularly in
Dukes A-C. A clinically even more important issue is whether
the combination of CEA and CA 242 will show a similar
increase in sensitivity also for recurrent disease. According to
recently published results from Hall et al. (1994), the com-
bination ofCEA and CA 242 seems promising also in follow-
up of patients with colorectal cancer, and this issue will also
be evaluated in our patients in an ongoing study.
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